Interleukin-23 Antagonists

Interleukin-23 Antagonist

Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="section-8"></a><h1>11 DESCRIPTION</h1>Risankizumab-rzaa, an interleukin-23 (IL-23) antagonist, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. Risankizumab-rzaa is produced by recombinant DNA technology in Chinese hamster ovary cells and has an approximate molecular weight of 149 kDa. SKYRIZI (risankizumab-rzaa) injection 90 mg/mL prefilled syringe for subcutaneous useEach SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution. Each syringe delivers 90 mg of risankizumab-rzaa, and inactive ingredients polysorbate 20 (0.2 mg), sodium succinate (0.63 mg), sorbitol (41 mg), succinic acid (0.059 mg), and Water for Injection, USP. The pH is 6.2.SKYRIZI (risankizumab-rzaa) injection 150 mg/mL prefilled syringe or prefilled pen for subcutaneous use Each SKYRIZI prefilled pen or prefilled syringe contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each syringe and pen delivers 150 mg of risankizumab-rzaa and the inactive ingredients glacial acetic acid (0.054 mg), polysorbate 20 (0.2 mg), sodium acetate (0.75 mg), trehalose (63.33 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI (risankizumab-rzaa) injection 180 mg/1.2mL (150 mg/mL) prefilled cartridge for use with supplied on-body-injector for subcutaneous useEach SKYRIZI prefilled cartridge contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each cartridge delivers 180 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.065 mg), polysorbate 20 (0.24 mg), sodium acetate (0.9 mg), trehalose (76 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI (risankizumab-rzaa) injection 360 mg/2.4 mL (150 mg/mL) prefilled cartridge for use with the supplied on-body injector for subcutaneous use Each SKYRIZI prefilled cartridge contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each cartridge delivers 360 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.13 mg), polysorbate 20 (0.48 mg), sodium acetate (1.8 mg), trehalose (152 mg), and Water for Injection, USP. The pH is 5.7.SKYRIZI 600 mg/10 mL (60 mg/mL) in a vial for intravenous infusionSKYRIZI (risankizumab-rzaa) injection 600 mg/10 mL (60 mg/mL) is a sterile, preservative-free, colorless to slightly yellow, and clear to slightly opalescent solution in a 10 mL single-dose vial.Each 10 mL single-dose vial contains 600 mg of risankizumab-rzaa, and the inactive ingredients glacial acetic acid (0.54 mg), polysorbate 20 (2 mg), sodium acetate (7.5 mg), trehalose (633.3 mg), and Water for Injection, USP. The pH is 5.7.</section>

Skyrizi

risankizumab

risankizumab-rzaa

1 ML risankizumab-rzaa 150 MG/ML Auto-Injector

1 ML risankizumab-rzaa 150 MG/ML Auto-Injector [Skyrizi]

1 ML risankizumab-rzaa 150 MG/ML Prefilled Syringe

1 ML risankizumab-rzaa 150 MG/ML Prefilled Syringe [Skyrizi]

10 ML risankizumab-rzaa 60 MG/ML Injection

10 ML risankizumab-rzaa 60 MG/ML Injection [Skyrizi]

2.4 ML risankizumab-rzaa 150 MG/ML Cartridge

2.4 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi]

1.2 ML risankizumab-rzaa 150 MG/ML Cartridge

1.2 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi]

1 ML risankizumab-rzaa 90 MG/ML Prefilled Syringe

1 ML risankizumab-rzaa 90 MG/ML Prefilled Syringe [Skyrizi]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Skyrizi, an interleukin inhibitor, is prescribed to alleviate inflammation associated with plaque psoriasis, psoriatic arthritis, or Crohn's disease in adults. The recommended dose is 150mg administered every 12 weeks as two subcutaneous injections of 75mg, which patients can learn to self-administer. The most frequently reported side effects are upper respiratory tract infections, headache, and fatigue.

Skyrizi is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, and Crohn’s Disease. 


Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Billing and Coding Guide 

Reimbursement Information 

Formulary Information

Coverage Authorization Request

Coverage Authorization Appeals

Letter of Medical Necessity 

Formulary Exception Letter 

Tiered Exception Letter 

HIPAA Authorization Template

Navigating PA 

Guide To Starting Skyrizi 

Skyrizi Complete Prescription & Enrollment Form: Rheumatology & Dermatology 

Skyrizi Complete Prescription & Enrollment Form: Gastroenterology

Complete by Abbvie {HCP Portal}

Enroll in Patient Savings Program

Enroll in Bridge Program 

Other HCP Resources: Plaque Psoriasis 

Skyrizi Complete App 

Other HCP Resources: Psoriatic Arthritis 

Other HCP Resources: Crohn's Disease

Patient Brochure: Plaque Psoriasis 

Quick Tips For Self Injecting - 150mg Pen 

Quick Tips For Injecting - 150mg Prefilled Syringe

Skyrizi Complete Support Program 

Nurse Ambassador 

Sharps Container 

About Skyrizi: Plaque Psoriasis 

Taking Skyrizi: Plaque Psoriasis & Psoriatic Arthritis 

Side Effects: Plaque Psoriasis & Psoriatic Arthritis 

Before and After: Plaque Psoriasis 

Patient Stories: Plaque Psoriasis

Doctor Discussion Guide: Plaque Psoriasis & Psoriatic Arthritis 

Prep For Your Appointment: Plaque Psoriasis & Psoriatic Arthritis 

Instructions For Use: Plaque Psoriasis 

Instructions For Use: Psoriatic Arthritis 

About Skyrizi: Psoriatic Arthritis 

About Skyrizi: Crohn's Disease 

Taking Skyrizi: Crohn's Disease 

Side Effects: Crohn's Disease 

Doctor Discussion Guide: Crohn's Disease 

Infusion Support: Crohn's Disease 

Infusion Prep Guide: Crohn's Disease 

On-Body Injector (OBI) Prep Guide: Crohn's Disease

Instructions For Use: Crohn's Disease 

Infusion To On-Body Injector (OBI) Guide 